<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_1896393598-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_1896393598-430x241.jpg"/></p>
<p>英國通過 VPAG 計劃將 2026 年的創新藥物回扣率降低至 14.5%。圖片來源：Vitalii Stock via Shutterstock.com。</p>
<p>英國政府將其創新藥物回扣率削減超過三分之一，此舉可能會受到製藥行業的歡迎。</p>
<p>這意味着在 2026 年向英國國家健康服務體系（NHS）提供新一代療法的製藥公司將通過品牌藥物定價自願計劃（VPAG）支付 14.5% 的回扣。這一比例較 2025 年的回扣率 22.9% 大幅下降。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>生物製藥行業現狀 2023</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>法國 - 醫療、監管和報銷環境</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>與此同時，2026 年老牌藥物的回扣率將保持不變，維持在 10%-35% 之間，具體取決於療法。</p>
<p>除了對老藥和新藥的提議回扣率外，NHS 還將通過預種子投資資金組件獲得 1% 的資金，這意味着新藥的回扣率將達到 15.5%。</p>
<p>根據英國衞生與社會護理部的説法，該計劃將提升英國作為臨牀試驗和製造中心的吸引力，同時將該國定位為新藥早期上市的有利地點。</p>
<p>這一回扣變化緊隨英國政府與特朗普政府達成的 里程碑協議。根據該協議，英國在向美國進口藥品時將不再支付關税，使其成為第一個達成此類協議的國家。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預測？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>由 GlobalData 提供</p>
<p>瞭解更多關於戰略情報</p>
<p>作為關税豁免的交換，英國將通過 NHS 增加對創新藥物的支出，正如該國的藥物支出監管機構國家健康與護理卓越研究所（NICE）所允許的。這是 NICE 在過去二十多年中首次提高成本效益閾值。</p>
<p>根據英美協議，英國在 2027 年和 2028 年設定了 15% 的回扣上限，英國製藥工業協會（ABPI）首席執行官 Richard Torbett 指出，這將 “為公司提供更大的確定性”，直到截止期。</p>
<p>儘管這是向前邁出的積極一步，Torbett 指出，仍需更多努力使英國重新回到全球競爭的地位：“支付率仍遠高於類似國家，NHS 在採用和使用成本效益藥物方面還有待加快。”</p>
<p>與此同時，慈善藥物獲取聯盟主席 Scott Purdon 博士讚揚了政府的舉措，指出如果回扣減少能帶來更大的投資和更廣泛的治療獲取，將會帶來 “顯著的好處”。</p>
<p>GlobalData 健康經濟學和市場準入的管理分析師 Janet Beal 指出：“最近達成的 VPAG 回扣上限為 15% 不需要在 2026 年適用，而通過標準機制計算出的較低數字 14.5% 可能會讓英國製藥行業感到相當驚喜和歡迎。”</p>
<p>展望未來，Beal 預測大多數成員公司 “極有可能” 選擇在接下來的一年內繼續留在該計劃中，因為 “目前設定的 2026 年強制性備份法定計劃的回扣率為 24.3% 是一個明顯劣勢的選擇”。</p>
<h2>英國尋求修復製藥關係</h2>
<p>通過回扣的變化和與美國的協議，英國正在 努力改善 與製藥行業的關係，最近由於對該行業投資不足而變得緊張。</p>
<p>這促使一系列大型製藥公司停止在英國的研發擴展努力，包括 MSD、阿斯利康 和賽諾菲。</p>
<p>根據《金融時報》的採訪，艾利 Lilly 首席執行官大衞·裏克斯稱英國 “可能是歐洲藥品價格最糟糕的國家”，這在美英協議簽署之前。儘管裏克斯對協議持樂觀態度，但該公司最近告訴該出版物，它尚未準備好解凍在英國的投資。</p>
<p>對英國的生命科學外商直接投資也受到影響，在 2021 年至 2023 年間下降了 58%，這突顯了投資者信心可能下降。</p>
<p>英國現在希望通過恢復與行業的關係來扭轉其命運。</p>
<p>在一份研究報告中，全球法律公司 Sidley Austin 表示，如果英國有任何機會實現這一目標，該國需要 “保持對生命科學的新承諾和投資”。</p>
<p>Sidley 團隊總結道：“英國必須繼續利用 MHRA 作為主權監管機構的地位，並消除過於複雜的障礙，以便在英國建立和擴大製藥公司。”</p>
<h2>製藥技術卓越獎 - 提名已關閉</h2>
<p>製藥技術卓越獎 的提名現已關閉。非常感謝所有參與的組織——你們的反饋非常出色，展示了卓越的創新、領導力和影響力。</p>
<p><strong>行動中的卓越</strong></p>
<p>Imagene 的 腫瘤智能 (OI) 套件 榮獲精準腫瘤學創新獎，因其改變了製藥公司設計和進行腫瘤試驗的方式。從 AI 驅動的生物標誌物發現到更智能的患者分層，看看 Imagene 如何在癌症藥物開發中縮短時間、降低成本和風險。</p>
<p>發現影響</p>

<p>英國在 2026 年將其創新藥物回扣率在 VPAG 計劃下降低至 14.5%，較 2025 年的 22.9% 有所下降。這一舉措旨在改善與製藥行業的關係，並提升英國在臨牀試驗和新藥上市方面的吸引力。此變化是在一項英美協議之後，該協議免除了英國藥品進口的美國關税，同時英國還增加了對創新藥物的 NHS 支出。儘管這是一個積極的步驟，但仍需進一步努力以增強英國在製藥行業的全球競爭力</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_1896393598-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/12/shutterstock_1896393598-430x241.jpg"/></p>
<p>The UK has reduced the innovative medicines rebate rate for 2026 through the VPAG scheme down to 14.5%. Image credit: Vitalii Stock via Shutterstock.com.</p>
<div class="lb-trans"><p>英國通過 VPAG 計劃將 2026 年的創新藥物回扣率降低至 14.5%。圖片來源：Vitalii Stock via Shutterstock.com。</p>
</div><p>The UK Government has cut its innovative medicine rebate rate by more than a third in a move likely to be welcomed by the pharma industry.</p>
<div class="lb-trans"><p>英國政府將其創新藥物回扣率削減超過三分之一，此舉可能會受到製藥行業的歡迎。</p>
</div><p>This means pharma companies providing new, next-generation therapies to the UK’s National Health Service (NHS) in 2026 will now pay 14.5% back through the Voluntary Scheme for Branded Medicines Pricing (VPAG). This is down significantly from the 2025 clawback rate, which sat at 22.9%.</p>
<div class="lb-trans"><p>這意味着在 2026 年向英國國家健康服務體系（NHS）提供新一代療法的製藥公司將通過品牌藥物定價自願計劃（VPAG）支付 14.5% 的回扣。這一比例較 2025 年的回扣率 22.9% 大幅下降。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>State of the Biopharmaceutical Industry 2023</h4>
<div class="lb-trans"><h4>生物製藥行業現狀 2023</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>France - Healthcare, Regulatory and Reimbursement Landscape</h4>
<div class="lb-trans"><h4>法國 - 醫療、監管和報銷環境</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Meanwhile, payback rates for older, branded medicines will remain unchanged in 2026, standing at a rate of 10%-35%, depending on the therapy.</p>
<div class="lb-trans"><p>與此同時，2026 年老牌藥物的回扣率將保持不變，維持在 10%-35% 之間，具體取決於療法。</p>
</div><p>In addition to the proposed rates for both older and newer drugs, the NHS will receive 1% through a pre-seed investment funding component, meaning the newer medicines will see a clawback rate of 15.5%,</p>
<div class="lb-trans"><p>除了對老藥和新藥的提議回扣率外，NHS 還將通過預種子投資資金組件獲得 1% 的資金，這意味着新藥的回扣率將達到 15.5%。</p>
</div><p>According to the UK’s Department of Health &amp; Social Care, this scheme will boost the UK’s attractiveness as a hub for clinical trials and manufacturing, while positioning the nation as a favourable location for the early launch of new medicines.</p>
<div class="lb-trans"><p>根據英國衞生與社會護理部的説法，該計劃將提升英國作為臨牀試驗和製造中心的吸引力，同時將該國定位為新藥早期上市的有利地點。</p>
</div><p>This rebate change closely follows the UK Government’s landmark deal with the Trump administration. The agreement will see the UK pay no tariffs on pharmaceutical imports into the US, making it the first country to arrange such a deal.</p>
<div class="lb-trans"><p>這一回扣變化緊隨英國政府與特朗普政府達成的 里程碑協議。根據該協議，英國在向美國進口藥品時將不再支付關税，使其成為第一個達成此類協議的國家。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預測？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><p>In exchange for this tariff exemption, the UK will increase its spending on innovative medicines through the NHS, as permitted by the nation’s drug spending watchdog, the National Institute for Health and Care Excellence (NICE). This marks the first increase in the NICE’s cost-effectiveness threshold in more than two decades.</p>
<div class="lb-trans"><p>作為關税豁免的交換，英國將通過 NHS 增加對創新藥物的支出，正如該國的藥物支出監管機構國家健康與護理卓越研究所（NICE）所允許的。這是 NICE 在過去二十多年中首次提高成本效益閾值。</p>
</div><p>As agreed in the UK-US deal, the UK has placed a 15% clawback cap throughout 2027 and 2028, which Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), noted would “provide companies with greater certainty” until the cut-off period.</p>
<div class="lb-trans"><p>根據英美協議，英國在 2027 年和 2028 年設定了 15% 的回扣上限，英國製藥工業協會（ABPI）首席執行官 Richard Torbett 指出，這將 “為公司提供更大的確定性”，直到截止期。</p>
</div><p>Despite this positive step forward, Torbett noted that more work would be necessary to get the UK back into a competitive global position: “Payment rates remain much higher than in similar countries, and there is work to do to accelerate the NHS’s adoption and use of cost-effective medicines.”</p>
<div class="lb-trans"><p>儘管這是向前邁出的積極一步，Torbett 指出，仍需更多努力使英國重新回到全球競爭的地位：“支付率仍遠高於類似國家，NHS 在採用和使用成本效益藥物方面還有待加快。”</p>
</div><p>Meanwhile, Dr Scott Purdon, chair of the Charity Medicines Access Coalition, praised the government’s move, noting that the announcement will bring “significant benefit” if the clawback reduction results in greater investment and broader therapeutic access.</p>
<div class="lb-trans"><p>與此同時，慈善藥物獲取聯盟主席 Scott Purdon 博士讚揚了政府的舉措，指出如果回扣減少能帶來更大的投資和更廣泛的治療獲取，將會帶來 “顯著的好處”。</p>
</div><p>Janet Beal, managing analyst of health economics and market access, Europe/CIS at GlobalData noted: “The fact that the recently agreed VPAG headline payback cap of 15% did not need to be applied for 2026, and a lower figure of 14.5% has been calculated by the standard mechanism is likely to come as a considerable and welcome surprise to the UK’s pharma sector.”</p>
<div class="lb-trans"><p>GlobalData 健康經濟學和市場準入的管理分析師 Janet Beal 指出：“最近達成的 VPAG 回扣上限為 15% 不需要在 2026 年適用，而通過標準機制計算出的較低數字 14.5% 可能會讓英國製藥行業感到相當驚喜和歡迎。”</p>
</div><p>Moving forward, Beal predicts that it is “highly likely” that a majority of member companies will opt to remain in the scheme for at least the next year, as the “currently set 24.3% payback rate for 2026 on the mandatory backup Statutory Scheme represents a considerably inferior option”.</p>
<div class="lb-trans"><p>展望未來，Beal 預測大多數成員公司 “極有可能” 選擇在接下來的一年內繼續留在該計劃中，因為 “目前設定的 2026 年強制性備份法定計劃的回扣率為 24.3% 是一個明顯劣勢的選擇”。</p>
</div><h2>UK looks to repair pharma relations</h2>
<div class="lb-trans"><h2>英國尋求修復製藥關係</h2>
</div><p>Through the change to rebates and its deal with the US, the UK is making strides to improve relations with the pharmaceutical industry, which have recently been souring due to a lack of investment in the sector.</p>
<div class="lb-trans"><p>通過回扣的變化和與美國的協議，英國正在 努力改善 與製藥行業的關係，最近由於對該行業投資不足而變得緊張。</p>
</div><p>This has prompted a range of big pharma companies to pull the plug on their UK R&amp;D expansion efforts, including MSD, AstraZeneca and Sanofi.</p>
<div class="lb-trans"><p>這促使一系列大型製藥公司停止在英國的研發擴展努力，包括 MSD、阿斯利康 和賽諾菲。</p>
</div><p>It also led Eli Lilly CEO David Ricks to call the UK “probably the worst country in Europe” for drug prices before the signing of the US-UK deal, according to an interview with <em>The Financial Times</em>. The company recently told the publication that it is not yet ready to unfreeze its UK investments, despite Ricks’ optimism following the deal.</p>
<div class="lb-trans"><p>根據《金融時報》的採訪，艾利 Lilly 首席執行官大衞·裏克斯稱英國 “可能是歐洲藥品價格最糟糕的國家”，這在美英協議簽署之前。儘管裏克斯對協議持樂觀態度，但該公司最近告訴該出版物，它尚未準備好解凍在英國的投資。</p>
</div><p>Life science foreign direct investment into the UK has also taken a hit, sinking 58% between 2021 and 2023, highlighting a potential drop in investor confidence.</p>
<div class="lb-trans"><p>對英國的生命科學外商直接投資也受到影響，在 2021 年至 2023 年間下降了 58%，這突顯了投資者信心可能下降。</p>
</div><p>The UK is now looking to turn its fate around by reviving its relationships with the industry.</p>
<div class="lb-trans"><p>英國現在希望通過恢復與行業的關係來扭轉其命運。</p>
</div><p>In a research note, global law company Sidley Austin stated that if the UK was to have any chance of achieving this goal, the nation will need to “maintain its new commitment and investment in life sciences”.</p>
<div class="lb-trans"><p>在一份研究報告中，全球法律公司 Sidley Austin 表示，如果英國有任何機會實現這一目標，該國需要 “保持對生命科學的新承諾和投資”。</p>
</div><p>“It will be necessary for the UK to … continue to take advantage of MHRA’s status as a sovereign regulator, and remove roadblocks that overcomplicate the establishment and scale up of pharma companies in the UK,” the Sidley team concluded.</p>
<div class="lb-trans"><p>Sidley 團隊總結道：“英國必須繼續利用 MHRA 作為主權監管機構的地位，並消除過於複雜的障礙，以便在英國建立和擴大製藥公司。”</p>
</div><h2>Pharmaceutical Technology Excellence Awards - Nominations Closed</h2>
<div class="lb-trans"><h2>製藥技術卓越獎 - 提名已關閉</h2>
</div><p>Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.</p>
<div class="lb-trans"><p>製藥技術卓越獎 的提名現已關閉。非常感謝所有參與的組織——你們的反饋非常出色，展示了卓越的創新、領導力和影響力。</p>
</div><p><strong>Excellence in Action</strong></p>
<div class="lb-trans"><p><strong>行動中的卓越</strong></p>
</div><p>Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.</p>
<div class="lb-trans"><p>Imagene 的 腫瘤智能 (OI) 套件 榮獲精準腫瘤學創新獎，因其改變了製藥公司設計和進行腫瘤試驗的方式。從 AI 驅動的生物標誌物發現到更智能的患者分層，看看 Imagene 如何在癌症藥物開發中縮短時間、降低成本和風險。</p>
</div><p>Discover the Impact</p>
<div class="lb-trans"><p>發現影響</p>
</div>

英國將 2026 年藥品回扣率削減三分之一，以重新贏得製藥行業的信任